Darwin AG Publishes Financial Figures and Provides Business Update for 2025

Munich, 12 May 2026 — 09:00 CET/CEST

Darwin AG (ISIN DE000A3C35W0) released its consolidated financial statements for the fiscal year ended 31 December 2025.

Key highlights: Group revenue exceeded EUR 54.3 million, more than doubling from EUR 25.3 million in 2024 (114% growth). The company closed the fiscal year with positive net income. Cash and securities totaled approximately EUR 53 million.

CEO Dr. Daniel Wallerstorfer stated: “The 2025 fiscal year marks the transition from strategic development to dynamic and profitable growth,” following completion of proprietary IT platform implementation begun in 2023.

Financial performance: the genetic testing and personalized products segment generated EUR 11.4 million (prior year: EUR 7.5 million), while pharmaceuticals and medical devices contributed EUR 42.9 million (prior year: EUR 17.8 million). Operating result (EBIT) was EUR -10.8 million compared to EUR 26.4 million previously, driven by substantial investments in new IT platform development. Consolidated net income totaled EUR 0.5 million versus EUR 18.5 million in 2024.

Financial position: cash and cash equivalents approximately EUR 12.5 million (prior year: EUR 20.7 million); securities held approximately EUR 40 million (2024: EUR 57.8 million).

Guidance for 2026: Darwin AG projects revenues exceeding EUR 65 million and positive EBIT for 2026. However, the company noted that “the business environment in the current fiscal year is more challenging than previously anticipated” due to geopolitical tensions in the Middle East, European economic weakness, and operational headwinds in online sales channels. Management currently anticipates moderate revenue growth and will provide more precise guidance once conditions stabilize.

About Novogenia AG (formerly Darwin AG): The Novogenia Group, headquartered in Munich, Germany, operates as a European healthcare company specializing in human genetics and personalized product development. The organization conducts genetic analyses in its own laboratory for disease diagnosis, treatment, prevention, and creation of customized nutritional supplements and cosmetics. Novogenia serves physicians, therapists, pharmacists, nutritionists, and fitness trainers while maintaining investments in biotech, healthcare, and life sciences enterprises.

Contact:
Novogenia AG (Investor Relations)
Brienner Str. 7, 80333 Munich
Tel: +49 89 20 500 450
investor.relations@novogenia.com

Originally distributed via EQS News under the company's then-current name, Darwin AG. Source: eqs-news.com.